# A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19

> **NCT04469621** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 68 (actual)

## Conditions studied

- Corona Virus Infection

## Interventions

- **DRUG:** SAR443122
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04469621
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-17
- **Primary completion:** 2020-10-23
- **Final completion:** 2020-10-23
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04469621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04469621, "A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04469621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*